Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death

Human Mutation

Volumn 32, Issue 12, 2011, Pages 1390-1397

  Angeles, Dario C ^a   Gan, Bong Hwa ^a   Onstead, Luisa ^b   Zhao, Yi ^c   Lim, Kah Leong ^d   Dachsel, Justus ^e   Melrose, Heather ^e   Farrer, Matt ^f   Wszolek, Zbigniew K ^e   Dickson, Dennis W ^b   Tan, Eng King ^a,c,d,g  

^a Singapore Health Services   (Singapore)

^b MAYO CLINIC   (United States)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^e MAYO GRADUATE SCHOOL   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Apoptosis; LRRK2; Oxidative damage; Peroxiredoxin 3; Phosphorylation

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PEROXIREDOXIN 3; REACTIVE OXYGEN METABOLITE; THIOREDOXIN;

AGED; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; OXIDATIVE STRESS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

CELL DEATH; HUMANS; MITOCHONDRIA; MUTATION; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; PEROXIREDOXIN III; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES;

EID: 81255208412     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21582     Document Type: Article

References (37)

1. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL. 2006. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60:557-569.
2. Bosgraaf L, Van Haastert PJ. 2003. Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643:5-10.
3. Chae HZ, Kang SW, Rhee SG. 1999. Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. Methods Enzymol 300:219-226.
4. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909.
5. Ellis HR, Poole LB. 1997. Roles for the two cysteine residues of AhpC in catalysis of peroxide reduction by alkyl hydroperoxide reductase from Salmonella typhimurium. Biochemistry 36:13349-13356.
6. Fujii J, Ikeda Y. 2002. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7:123-130.
7. Galter D, Westerlund M, Carmine A, Lindqvist E, Sydow O, Olson L. 2006. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 59:714-719.
8. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. 2006. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15:223-232.
9. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG. 2007. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313:3658-3670.
10. Hattori F, Murayama N, Noshita T, Oikawa S. 2003. Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J Neurochem 86:860-868.
11. Hirotsu S, Abe Y, Okada K, Nagahara N, Hori H, Nishino T, Hakoshima T. 1999. Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 kDa/proliferation-associated gene product. Proc Natl Acad Sci USA 96:12333-12338.
12. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B. 2008. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27:2432-2443.
13. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR. 2007. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405:307-317.
14. Jiang H, Ren Y, Zhao J, Feng J. 2004. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13:1745-1754.
15. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. 2005. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672-680.
16. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. 1998. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 273:6297-6302.
17. Kang SW, Chang TS, Lee TH, Kim ES, Yu DY, Rhee SG. 2004. Cytosolic peroxiredoxin attenuates the activation of Jnk and p38 but potentiates that of Erk in Hela cells stimulated with tumor necrosis factor-alpha. J Biol Chem 279:2535-2543.
18. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, Rhee SG. 2004. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA 101:16419-16424.
19. Lang AE, Lozano AM. 1998. Parkinson's disease. First of two parts. N Engl J Med 339:1044-1053.
20. Li L SW, Takano H, Nishimura N, Aoki Y, Takahashi R, Goto S, Kaifu T, Takai T, Obinata M. 2007. Increased susceptibility of MER5 (peroxiredoxin III) knockout mice to LPS-induced oxidative stress. Biochem Biophys Res Commun 355:715-721.
21. Liou AK LR, Li L, Zigmond MJ. 2008. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK Pathway. Neurobiol Dis 32:116-124.
22. McKenna O, Arnold G, Holtzman E. 1976. Microperoxisome distribution in the central nervous system of the rat. Brain Res 117:181-194.
23. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M. 2006. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139:791-794.
24. Nagatsu T, Sawada M. 2006. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 26:781-802.
25. Nonn L, Berggren M, Powis G. 2003. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 1:682-689.
26. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singleton AB. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600.
27. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, Lobbestael E, Baekelandt V, Taymans JM, Sun L, Cai H. 2009. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29:13971-13980.
28. Pridgeon JW, Olzmann JA, Chin LS, Li L. 2007. PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1. PLoS Biol 5:e172.
29. Rhee SG, Chae HZ, Kim K. 2005. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38:1543-1552.
30. Shen J, Cookson MR. 2004. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 43:301-304.
31. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. 2006. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231-1233.
32. Spencer JP, Jenner A, Aruoma OI, Evans PJ, Kaur H, Dexter DT, Jenner P, Lees AJ, Marsden DC, Halliwell B. 1994. Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett 353:246-250.
33. Tan EK, Skipper LM. 2007. Pathogenic mutations in Parkinson disease. Hum Mutat 28:641-653.
34. Tsuchiya Y, Okuno Y, Hishinuma K, Ezaki A, Okada G, Yamaguchi M, Chikuma T, Hojo H. 2007. 4-Hydroxy-2-nonenal-modified glyceraldehyde-3-phosphate dehydrogenase is degraded by cathepsin G. Free Radic Biol Med 43:1604-1615.
35. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, Moore DJ, Dawson TM, Dawson VL, Chiosis G, Cookson MR, Cai H. 2008. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28:3384-3391.
36. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102:16842-16847.
37. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB and others. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607.